Leap Therapeutics, Inc.
LPTX
$0.369
-$0.0053-1.42%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -6.96% | -4.51% | -0.59% | 6.40% | 17.03% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -18.48% | -18.38% | -23.54% | -32.93% | 57.08% |
| Operating Income | 18.48% | 18.38% | 23.54% | 32.93% | -57.08% |
| Income Before Tax | 17.45% | 20.75% | 26.68% | 37.89% | -49.52% |
| Income Tax Expenses | -- | 381.63% | -- | -- | -- |
| Earnings from Continuing Operations | 16.74% | 20.02% | 26.81% | 38.00% | -49.12% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 16.74% | 20.02% | 26.81% | 38.00% | -49.12% |
| EBIT | 18.48% | 18.38% | 23.54% | 32.93% | -57.08% |
| EBITDA | 18.47% | 18.38% | 23.54% | 32.93% | -57.10% |
| EPS Basic | 63.78% | 66.19% | 69.44% | 66.52% | -6.12% |
| Normalized Basic EPS | 56.92% | 66.52% | 69.47% | 66.45% | -6.41% |
| EPS Diluted | 63.78% | 66.19% | 69.44% | 66.52% | -6.12% |
| Normalized Diluted EPS | 56.92% | 66.52% | 69.47% | 66.45% | -6.41% |
| Average Basic Shares Outstanding | 82.06% | 103.67% | 138.82% | 104.02% | 80.18% |
| Average Diluted Shares Outstanding | 82.06% | 103.67% | 138.82% | 104.02% | 80.18% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |